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Various neonatal symptoms can lead to a diagnosis of congenital CMV infection. We report two cases of persistent pulmonary
hypertension in relation with congenital CMV infection following maternal primary infection and reinfection, respectively. Both
infants had severe refractory hypoxemia, requiring high-frequency ventilation, inhaled nitric oxide and inotropic support. One
of them required extracorporeal membrane oxygenation for ﬁve days. Ganciclovir therapy was attempted in the two cases on
day 12 postnatal. One of the infant died on day 15 postnatal. The other survived and is developing uneventfully at 15 months
of age. Conclusion: Neonatal persistent pulmonary hypertension can be the consequence of congenital CMV infection. Intensive
respiratory support and IV ganciclovir are indicated in case of life-threatening condition.
1.Introduction
Cytomegalovirus (CMV) is one of the most common
causes of congenital infection in the developed countries,
aﬀecting approximately 1% of all live births. Most of
infected infants will remain asymptomatic, but about 10%
of infected newborns will have symptomatic disease and
10–15% will develop problems during the ﬁrst 6 years of
life [1]. Symptoms include growth restriction, microcephaly,
seizures, cerebral ventriculomegaly, chorioretinis, hepatitis
syndrome,thrombocytopenia,anemia, andpneumonitis[2].
Preconceptional maternal immunity does not provide com-
plete protection to the fetus, and congenital CMV infection
may occur in infants of mother who are seropositive for
CMVpriortopregnancy.Theoutcomeofrecurrentmaternal
infectionmaybesevere[3,4].Thebeneﬁtofantiviraltherapy
in congenital CMV infection is still controversial [5, 6]. We
present two cases of congenital CMV disease presenting with
severe persistent pulmonary hypertension (PPH).
Case 1. A 30-year-old woman in her second normal preg-
nancy delivered vaginally a 2940g (25th percentile) female
infant with a head circumference of 34cm (50th percentile)
at 39 weeks gestation. Maternal asthenia and fever compli-
cated the antenatal course at 31-week gestation. No prenatal
abnormal ultrasonographic ﬁnding was recorded. Apgar
score was 10 at 1 and 5 minutes. Mechanical ventilation
was initiated in the ﬁrst hour of life for acute respiratory
distress. Chest X-Ray showed alveolo-interstitial pneumoni-
tis. Antibiotic therapy including amoxicillin, cefotaxime,
and amikacin was initiated. Despite mechanical ventilation,
refractory hypoxemia developed within 12 hours of life.
Echocardiogram showed a structurally normal heart and2 Pulmonary Medicine
diagnosed pulmonary hypertension (peak velocity of tricus-
pid regurgitation at 4m/sec, pure right-to-left shunt at both
atrial and ductal level, and reduced mean pulmonary blood
velocity at 0.19m/sec). Despite high-frequency ventilation
(HFV), inhaled nitric oxide (NO) (20ppm), inotropic
support (dobutamine 10μg/kg/min), and surfactant therapy
(Curosurf 200mg/kg), the infant’s condition deteriorated.
Hepatomegaly and splenomegaly were noted on day 5.
BiologicalabnormalitiesincludedelevatedC-reactiveprotein
(80mg/L), thrombocytopenia (61 × 109/L), neutropenia
(0.37 × 109/L), elevated conjugated bilirubinemia (total
serum bilirubin 285μmol/L; direct bilirubin 185μmol/L),
and aspartate aminotransferase (207UI/L). Cultures for
b a c t e r i aa n df u n g iw e r en e g a t i v e .C M Vw a si s o l a t e di nt h e
urines and in the blood plasma by PCR performed on
day 12. Intravenous ganciclovir treatment (12mg/kg/d) and
polyclonal immunoglobulin G (Octagam 1g/kg every 24
hours for 2 days) were initiated. Severe hypoxemia persisted
with progressive hypercapnia. Chest X-ray found severe pul-
monary interstitial emphysema. The patient died on day 15.
Parentsdeclinedpostmortemexaminationandpercutaneous
lung biopsy. Maternal seroconversion during the seventh
month of pregnancy was conﬁrmed by retrospective analysis
of maternal serum sample taken monthly for toxoplasmosis
testing (IgG < 0.4UI/l and IgM < 0.9UI/l on the 7th month
ofgestationand IgG = 0.7UI/landIgM =2.9UI/lonemonth
latter) with ETI-CMV-G and ETI-CMV-M assays (DiaSorin,
France).
Case 2. A3 3 - y e a r - o l dw o m a ni nh e rs e c o n dn o r m a lp r e g -
nancy delivered vaginally a 2520g (20th percentile) male
infant, with a head circumference of 32cm (10th percentile)
at 37 weeks gestation. Apgar score was of 7 and 8 at 1 and
5 minutes, respectively, and the infant required mechanical
ventilationforpersistentcyanosis. Chestradiographsshowed
moderate alveolar syndrome. Echocardiography conﬁrmed
an anatomically normal heart and pulmonary hypertension
(pure right-to-left shunt at both atrial and ductal level,
hypertrophy of right ventricle, and intermittent tricuspid
regurgitation). Blood cell count showed marked throm-
bocytopenia (20 × 109/L) with normal leucocytes count.
Amoxicillin and gentamicin therapy was initiated.
Despite HFV, adjunction of NO (20ppm), and
inotropic support (dobutamine 20γ/kg/min, epinephrine
0.5γ/kg/min), PPH worsened and was associated with
refractory hypoxemia. The infant required extracorporeal
membrane oxygenation support for 5 days. He tolerated
the withdrawal of NO on day 4 and weaning of ECMO
on day 8. FiO2 was decreased to 50%. Echocardiogram
revealed infrasystemic pulmonary hypertension and
moderate hypertrophy of the right ventricle. After transient
respiratory improvement, echocardiogram conﬁrmed severe
exacerbation of PPH. HFV, 100% FiO2, adjunction of NO
(20ppm), and pulmonary vasoactive agent (prostacyclin
40ng/kg/min) were required.
Blood culture and gastric swab were negative for bacteria
and fungi. Because of neonatal thrombocytopenia, urine was
screened for cytomegalovirus (CMV) on day 1 and con-
ﬁrmed congenital CMV infection (17500copies/ml). CMV
DNA was detected by PCR in blood sample and broncho-
alveolar lavage (BAL) on day 12 (resp., 500copies/mL
and 1520copies/mL). Simultaneously, the patient presented
jaundice and hepatosplenomegaly. Conjugated hyperbiliru-
binemia (total serum bilirubin 101μmol/L; direct bilirubin
73μmol/L) was noted. Platelet count was normal (238 ×
109/L). Intravenous ganciclovir (10mg/kg/d) was initiated
on day 13 and prolonged for 6 weeks with no side eﬀect.
CMV DNA ampliﬁcation became negative in broncho-
alveolar lavage, blood, and urine within two weeks, and the
respiratory status slowly improved. NO was progressively
decreased until withdrawal at day 25. The infant was
successfully weaned of the ventilator on day 32, and oxygen
therapy was needed until day 56. Cholestasis progressively
resolved. Neurological status remained normal. Ophthalmo-
logic examination ruled out CMV retinitis. Head CT scan
showed bilateral subependymal cysts without calciﬁcations.
The infant was discharged at 2 months. Echocardiogram was
normal from the 3rd month of life and remained normal
at 9 months. Clinical and neurological examination at 15
months was normal. Auditory brainstem evoked responses
were normal at 10-month followup.
Positive CMV-speciﬁc IgG (46U/mL) of high avidity
(96%) (VIDAS CMV IgG, BioM´ erieux, France) and negative
IgM (VIDAS CMV IgGM) detected on maternal serum
collected at 20 weeks of gestation were in favour of pre-
existing immunity. CMV-speciﬁc IgG antibody levels were
comparable between the serum sample collected at 29-week
gestation and at birth.
2.Discussion
We report two cases of congenital cytomegalovirus infection
presenting at birth with PPH and refractory hypoxemia.
Neonatal PPH is usually associated with perinatal asphyxia,
meconium aspiration syndrome, hyaline membrane disease,
or bacterial infection. These causes were excluded in these
two cases, and PPH was most probably a direct complication
of CMV congenital pneumonitis. Pneumonitis is rarely the
only manifestation ofcongenital CMVdisease in neonate [7]
and its incidence is low [8]. To our knowledge, only one case
of congenital CMV infection presenting as severe PPH was
previously reported [9].
CMV spreads into the lungs following fetal viremia.
Usual pathological ﬁndings in congenitally infected fetal
lungs are immature and dystelectatic lungs associated with
interstitial oedema, the absence of cellular reaction, or puru-
lent inﬂammation [10, 11]. Vasculitis is another suspected
pathogenic mechanism leading to neonatal demise [12, 13].
In allogenic transplant recipients, CMV pneumonitis was
described as an immunopathogenic mechanism due to a
T-cell response to viral antigens expressed on lung cells
[14]. However, a case of extensive CMV infection presented
with severe pulmonary hypertension has been reported
in an adult with acquired immune deﬁciency syndrome
[15]. Post-mortem examination showed infection in the
lung endothelial cells. Enlarged CMV-infected endothelial
cells protruded into and compromised the lumens of thePulmonary Medicine 3
small vessels, leading to a signiﬁcant increase in pulmonary
arterial resistances. According to these pathologic features,
pulmonaryhypertension maybetransientifspeciﬁc antiviral
therapy is initiated. Respiratory support including mechan-
ical ventilation, NO, and ECMO should be initiated and
maintained as long as pulmonary hypertension persists.
Thesemeasuresmayhelptocontrolrespiratory statusaslong
as antiviral therapy may be eﬀective.
Antiviral treatment options are limited. Ganciclovir was
ﬁrst used in children over 20 years ago, but the optimal
dose, duration, and route of administration remain poorly
evidence based [6]. The beneﬁts of early treatment with
ganciclovir in congenital CMV infection, especially on
sensorineural hearing loss, remain controversial [16, 17].
However, congenitally infected infants with severe organ
disease such as pneumonitis, oesophagitis, persistent severe
thrombocytopenia, and active sight-threatening choriore-
tinitis appeared to beneﬁt from ganciclovir therapy [5, 18].
In the ﬁrst case reported here, respiratory status was severely
aﬀected when ganciclovir was initiated. This precluded
expecting a signiﬁcant improvement. In the second case,
when ganciclovir therapy was associated with respiratory
support, respiratory status improved and the patient recov-
ered.Wedidnotobserveanysideeﬀectalthoughganciclovir-
related severe but reversible neutropenia has been reported
in two-thirds of the treated infants [16]. This suggests that
the administration of antiviral therapy is appropriate in
severe condition attributed to CMV infection. However,
larger studies should be designed to drive further evidence
on clinical beneﬁt of this treatment.
Polyclonal globulins in association with ganciclovir were
used in the ﬁrst case. Speciﬁc anti-CMV immunoglobulins
are not available in France. CMV immunoglobulin therapy
has not been directly evaluated for the treatment of neonates
with symptomatic congenital CMV disease, but it may be
eﬀective in case of transfusion-acquired CMV infection
[18]. The beneﬁt of using CMV immunoglobulins has been
evaluated in the prevention of CMV disease after lung
transplantation butfailed to improve outcome [19]. In CMV
seropositive autologous hematopoietic stem cell recipients,
the outcome of CMV pneumonia remains poor despite
treatment withganciclovir andCMV hyperimmune globulin
administration [20].
Preconceptional immunity to CMV provides incomplete
protection, and congenital CMV infection can occur in
infants following both primary and recurrent infection in
the mother [21]. Although the latter is less prevalent, the
prognosis of fetal infection is similar to that following
primary infection [3, 4, 21]. Recurrent infection is caused
either by reinfection with a new CMV strain or reactivation
of a latent infection [18]. Reactivation of CMV infection
during pregnancy is reported in 10–30% of seropositive
women, and the risk of transmitting the virus is about 1–3%
[22]. In the second case, we reported CMV-positive urine on
the ﬁrst day of life excluded a postnatal CMV infection. In
case of maternal recurrent infection, we can hypothesize that
maternalantibodiesinassociationwithantiviraltherapymay
help to recovery.
3.Conclusion
This report highlights the potentialimplication ofcongenital
CMV in severe PPH, even in case of recurrent maternal
CMVinfection. PPHshouldbesystematically investigatedby
echocardiography in cases of congenital CMV pneumonitis.
Severe neonatal PPH with no obvious aetiology should
imply searching for congenital CMV infection. In cases
with life-threatening PPH, the administration of antiviral
therapy appears appropriate, associated with respiratory
support including extracorporeal ventilation, as long as
severe neurological impairment has been excluded. The
severity of the clinical condition and progressive end-organ
disease outweigh the potential toxicity of this treatment.
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